Want to see AU:CHM full AI Analyst Report?
Top Page
Chimeric Therapeutics Ltd.
(Sydney:CHM)
Select Model
Select Model
Rating:39Underperform
Price Target:
AU$0.01
â–²(0.00% Upside)
Action:Downgraded
Date:09/06/26
The score is driven primarily by very weak financial performance (revenue collapse, persistent losses, heavy cash burn, and negative equity), which elevates financing and dilution risk. Technicals further pressure the score, showing strong bearish momentum with the price below key moving averages and a negative MACD. Valuation does not provide meaningful support due to ongoing losses and no dividend yield data.
Positive Factors
Specialized CAR-T oncology focus
A focused oncology cell-therapy strategy gives Chimeric a clear therapeutic identity and aligns its research with a significant unmet medical need. If clinical translation succeeds, concentrated expertise in CAR-T could support differentiated programs and longer-term partnering or commercialization opportunities.
Negative Factors
Revenue has collapsed to near-zero
The latest revenue collapse materially weakens the operating foundation and suggests that current activities are not generating a dependable commercial income stream. Without a sustained recovery, Chimeric remains reliant on funding or successful development milestones to support ongoing operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized CAR-T oncology focus
A focused oncology cell-therapy strategy gives Chimeric a clear therapeutic identity and aligns its research with a significant unmet medical need. If clinical translation succeeds, concentrated expertise in CAR-T could support differentiated programs and longer-term partnering or commercialization opportunities.
Read all positive factors
Chimeric Therapeutics Ltd. (CHM) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$767.25K
Dividend YieldN/A
Average Volume (3M)983.95K
Price to Earnings (P/E)―
Beta (1Y)1.61
Revenue Growth-100.00%
EPS Growth-46.98%
CountryAU
Employees3
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.95
Shares Outstanding95,906,425
10 Day Avg. Volume1,729,759
30 Day Avg. Volume983,949
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.26
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)AU$480.58M
Chimeric Therapeutics Ltd. Business Overview & Revenue Model
Company Description
Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical firm dedicated to developing and commercializing a diverse array of cell therapies designed to combat various cancers. Its lead natural killer (NK) cell platform, CHM 020...
How the Company Makes Money
null...
Chimeric Therapeutics Ltd. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
14
Very Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 3.97M | 7.46M | 4.51M | 2.62M |
| Gross Profit | 0.00 | 3.12M | 7.45M | 3.54M | 1.67M |
| EBITDA | -8.36M | -9.08M | -11.30M | -28.59M | -13.62M |
| Net Income | -18.81M | -10.43M | -12.53M | -25.92M | -15.90M |
Balance Sheet | |||||
| Total Assets | 1.28M | 21.57M | 15.27M | 22.38M | 34.88M |
| Cash, Cash Equivalents and Short-Term Investments | 800.14K | 5.76M | 3.05M | 5.37M | 18.38M |
| Total Debt | 679.85K | 0.00 | 3.59M | 0.00 | 0.00 |
| Total Liabilities | 9.00M | 19.60M | 12.80M | 16.71M | 9.17M |
| Stockholders Equity | -7.72M | 1.97M | 2.47M | 5.66M | 25.71M |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -7.28M | 10.11K | -16.43M | -13.69M |
| Operating Cash Flow | -10.78M | -7.28M | -7.54M | -16.32M | -13.15M |
| Investing Cash Flow | -249.34K | 0.00 | 0.00 | -112.19K | -577.86K |
| Financing Cash Flow | 6.08M | 10.05M | 8.26M | 253.38K | 9.50M |
Chimeric Therapeutics Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | AU$3.09B | -23.30 | -16.10% | ― | 555.67% | 49.08% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$13.54M | -2.74 | -164.96% | ― | -4.24% | 33.39% | |
42 Neutral | AU$36.78M | -0.22 | -414.10% | ― | ― | -2.15% | |
42 Neutral | AU$70.74M | -0.89 | -98.86% | ― | ― | -27.73% | |
40 Underperform | AU$22.30M | -11.00 | -88.14% | ― | ― | -200.00% | |
39 Underperform | AU$767.25K | >-0.01 | 349.88% | ― | -100.00% | -46.98% |
* Healthcare Sector Average
AU:CHM
Chimeric Therapeutics Ltd.
0.01
-0.16
-93.53%
AU:IMU
Imugene
0.07
-0.21
-75.71%
AU:1AI
Living Cell Technologies
0.01
<0.01
10.00%
AU:MSB
Mesoblast Limited
2.23
0.02
0.90%
AU:IMM
Immutep Ltd
0.05
-0.20
-81.22%
AU:CMB
Regeneus Ltd.
0.46
-0.05
-10.68%
Chimeric Therapeutics Ltd. Corporate Events
Chimeric Therapeutics Seeks ASX Quotation for 14.8 Million New Shares
Sep 4, 2026
Chimeric Therapeutics Ltd. has applied for quotation of 14,814,814 new ordinary fully paid shares on the ASX, with an issue date of September 4, 2026. The securities are being quoted following the exercise of options or conversion of other convert...
Chimeric Therapeutics posts deeper loss as IP impairments push it into net liabilities
Aug 31, 2026
Chimeric Therapeutics Limited is a biotechnology company focused on cell-based immunotherapies for cancer, including CAR-based programs such as CLTX and CDH-17, and remains in a pre-revenue, development-heavy phase typical of early-stage biotechs....
Chimeric Therapeutics Seeks ASX Quotation for 9.5 Million New Shares
Aug 21, 2026
Chimeric Therapeutics has applied to the ASX for quotation of 9,523,809 new ordinary fully paid shares, to be issued on 21 August 2026. The new securities arise from the exercise or conversion of existing options or other convertible instruments, ...
Chimeric Therapeutics Halts Trading Ahead of CDH17 Trial Results
Aug 17, 2026
Chimeric Therapeutics has requested a trading halt on its securities on the ASX, with the pause to remain in place until the earlier of an upcoming material announcement or the resumption of normal trading on 19 August 2026. The halt is tied to pe...
Chimeric Therapeutics Seeks Quotation of 1.85 Million New Shares on ASX
Aug 7, 2026
Chimeric Therapeutics Limited has applied for quotation on the ASX of 1,851,851 new fully paid ordinary shares, with an issue date of 7 August 2026. The new securities arise from the exercise or conversion of existing options or other convertible ...
Chimeric Therapeutics Reports Positive Trial Data and Launches Strategic Review
Jul 31, 2026
Chimeric Therapeutics Ltd. is an Australian cell therapy company developing advanced CAR T and NK cell treatments for solid and blood cancers, with flagship programs targeting gastrointestinal malignancies and acute myeloid leukemia. Its focus on ...
Chimeric Therapeutics Secures $1.62m R&D Tax Incentive Funding to Back Clinical Trials and Strategic Review
Jul 29, 2026
Chimeric Therapeutics has secured $1.62 million in funding from Endpoints Capital against its anticipated FY26 Research and Development Tax Incentive, providing early access to capital to support Phase 1/2 clinical trial activities and general wor...
Chimeric Flags Clinical and Regulatory Risks in Forward-Looking Disclaimer
Jul 28, 2026
Chimeric Therapeutics has issued a disclaimer emphasising that its presentation contains forward-looking statements, highlighting that actual outcomes may differ significantly due to various risks and uncertainties. The company notes potential del...
Chimeric Therapeutics Seeks ASX Quotation for 1.55m New Shares
Jul 22, 2026
Chimeric Therapeutics Limited has applied for quotation of 1,550,387 ordinary fully paid shares on the ASX, to be issued on July 22, 2026. The new securities arise from the exercise of options or conversion of other convertible instruments and wil...
Chimeric Therapeutics Seeks ASX Quotation for Additional Shares
Jul 14, 2026
Chimeric Therapeutics Limited has applied for quotation of 1,410,256 new ordinary fully paid shares on the ASX, with an issue date of 14 July 2026. The additional securities, arising from the exercise or conversion of existing instruments, will ma...
Chimeric Therapeutics Reports Expiry of 45,000 Unexercised Options
Jul 14, 2026
Chimeric Therapeutics has notified the market of the cessation of 45,000 listed options, CHMAY, which expired on July 13, 2026 without being exercised or converted. The expiry slightly reduces the company’s pool of potential future equity, b...
Chimeric Therapeutics Details Director Exit and Post-Consolidation Option Holdings
Jul 7, 2026
Chimeric Therapeutics Limited has announced the cessation of Eric Sullivan as a director, effective 6 July 2026. The company has lodged a Final Director’s Interest Notice with the ASX detailing Sullivan’s remaining interests in company...
Chimeric Therapeutics Board Member Eric Sullivan Retires
Jul 5, 2026
Chimeric Therapeutics announced that independent non-executive director Eric Sullivan has retired from its board, effective immediately, citing personal reasons. Sullivan, who joined the board in August 2023, had served as chairman of the Audit an...
Chimeric Therapeutics Seeks Quotation for 1.77 Million New ASX Shares
Jul 2, 2026
Chimeric Therapeutics Limited has applied for quotation on the ASX of 1,770,833 new ordinary fully paid shares under its CHM ticker. The securities are scheduled to be issued and quoted on July 2, 2026, expanding the company’s listed share b...
Chimeric Therapeutics Launches Adviser-Led Strategic Review to Unlock Value
Jul 1, 2026
Chimeric Therapeutics has appointed Hawkesbury Partners as an independent financial adviser to lead a structured strategic review aimed at maximising shareholder value. The move follows more than A$80 million of investment in clinical programs and...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.